| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000020314 |
| Receipt No. | R000023449 |
| Official scientific title of the study | Effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors on metabolic parameters in patients with type 2 diabetes: A chart-based analysis |
| Date of disclosure of the study information | 2015/12/22 |
| Last modified on | 2016/12/22 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors on metabolic parameters in patients with type 2 diabetes: A chart-based analysis | |
| Title of the study (Brief title) | Effects of SGLT2 inhibitors in patients with type 2 diabetes | |
| Region |
|
|
| Condition | ||
| Condition | type 2 diabetes | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To understand the effects of SGLT2 inhibitors on metabolic parameters in patients with type 2 diabetes |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | body weight, blood pressure, plasma glucose, HbA1c, serum low-density lipoprotein-cholesterol (LDL), triglyceride (TG), high-density lipoprotein-cholesterol (HDL), non-HDL-cholesterol (non-HDL), aspartate aminotransferase (AST), alanine aminotransferase (ALT), eGFR |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | patients with type 2 diabetes, who had been prescribed SGLT2 inhibitors for 1 month or longer between April 2014 and November 2015 | |||
| Key exclusion criteria | none | |||
| Target sample size | 75 | |||
| Research contact person | |
| Name of lead principal investigator | Hisayuki Katsuyama |
| Organization | National Center for Global Health and Medicine Kohnodai Hospital |
| Division name | Department of Internal Medicine |
| Address | 1-7-1 Kohnodai, Ichikawa, Chiba, 272-0034, Japan |
| TEL | +81-47-272-0034 |
| katsuyama-hs@umin.org | |
| Public contact | |
| Name of contact person | Hisayuki Katsuyama |
| Organization | National Center for Global Health and Medicine Kohnodai Hospital |
| Division name | Department of Internal Medicine |
| Address | 1-7-1 Kohnodai, Ichikawa, Chiba, 272-0034, Japan |
| TEL | +81-47-272-0034 |
| Homepage URL | |
| katsuyama-hs@umin.org | |
| Sponsor | |
| Institute | National Center for Global Health and Medicine Kohnodai Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | none |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | https://www.ncbi.nlm.nih.gov/pubmed/27429679 |
| Publication of results | Published |
| URL releasing results | |
| Results | |
| Other related information | We compared the data at baseline and at 1, 2, 3 and 6 months after the start of SGLT2 inhibitors. Body weight, blood pressure, plasma glucose, HbA1c, serum low-density lipoprotein-cholesterol (LDL), triglyceride (TG), high-density lipoprotein-cholesterol (HDL), non-HDL-cholesterol (non-HDL), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in studied subjects were measured almost at the same time point at the baseline and at 1, 2, 3 or 6 months after the start of SGLT2 inhibitors. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000023449 |